Acadia Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ACAD research report →
Range $14.5 – $38
Price Chart
About the company
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders.
- CEO
- Catherine E. Owen Adams
- IPO
- 2004
- Employees
- 797
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on ACAD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.96B
- P/E
- 8.60
- Fwd P/E
- 22.24
- PEG
- 0.24
- P/S
- 2.63
- P/B
- 2.28
- EV/EBITDA
- 19.57
- Div Yield
- 0.00%
- Gross Margin
- 90.48%
- Op Margin
- 10.17%
- Net Margin
- 30.13%
- ROE
- 28.03%
- ROIC
- 8.29%
Latest fiscal year · YoY change
- Revenue
- $1.07B+11.9%
- Gross Profit
- $982.51M+12.2%
- Op Income
- $104.81M
- Net Income
- $391.00M+72.7%
- EPS
- $2.32+69.3%
- OCF Growth
- -30.4%
- FCF Growth
- -33.1%
- 52W High
- $30.96
- 52W Low
- $15.86
- 50D MA
- $21.01
- 200D MA
- $23.20
- Beta
- 0.89
- RSI (14)
- 34
- Avg Volume
- 2.17M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Acadia posted a strong Q3 with 22% adjusted revenue growth, record DAYBUE sales, solid NUPLAZID growth, and a more confident pipeline update despite a narrow Phase II miss in remlifanserin ADP.· November 4, 2026
- Total revenues were $342 million, up 22% year over year on an adjusted basis, led by both commercial brands.
- DAYBUE net sales hit a record $140 million, up 39% year over year, and management raised full-year DAYBUE guidance.
- NUPLAZID net sales were $202 million, up 12% year over year on an adjusted basis; guidance was narrowed, not raised, due to timing of field-force benefits.
- Remlifanserin Phase II in ADP narrowly missed the primary endpoint, but management said 60 mg showed a consistent signal and will advance into Phase III while 30 mg is being dropped.
- Cash ended the quarter at $976 million, and Acadia lowered full-year R&D and narrowed full-year revenue/expense ranges.
Q3 2026 total revenues were $342 million, up 22% year over year on an adjusted basis. DAYBUE net sales were $140 million, up 39% year over year, with a gross-to-net adjustment of 23.2%; NUPLAZID net sales were $202 million, up 12% year over year on an adjusted basis, with a gross-to-net adjustment of 22.7%. R&D expense was $76 million versus $88 million a year ago, SG&A was $159 million versus $133 million a year ago, and cash at quarter-end was $976 million. For full year 2026, Acadia now expects total revenues of $1.265 billion to $1.295 billion, DAYBUE net sales of $505 million to $520 million, NUPLAZID net sales of $760 million to $775 million, R&D of $325 million to $340 million, and SG&A of $665 million to $685 million. Gross-to-net assumptions for 2026 were updated to about 23% to 24% for DAYBUE and 22% to 23% for NUPLAZID.
Catherine Owen-Adams framed the quarter as evidence that Acadia’s commercial base is strong and that the company is translating that base into its next growth phase. She emphasized DAYBUE STIX, the new U.S. patent extending protection through March 2041, European approval and German launch, and the company’s continued confidence in long-term brand growth. On the pipeline, she said the remlifanserin data both narrowed uncertainty and increased confidence in the path forward, while also highlighting ACP-211 and the broader pipeline as multiple potential growth drivers.
Mark Schneyer focused on the quarter’s revenue mix, margin-related gross-to-net dynamics, and disciplined spending. He cited $342 million of adjusted revenue, $76 million of R&D, $159 million of SG&A, and $976 million in cash, and noted that R&D declined mainly because of lower spend on ending studies while SG&A rose because of field-force and marketing investments. He also updated 2026 guidance, including higher DAYBUE sales expectations, narrower NUPLAZID guidance, lower R&D, and a tightened revenue range, describing the balance sheet as a strategic asset that supports pipeline investment and business development.
Analysts focused heavily on three topics: how Acadia will optimize the Phase III remlifanserin design, whether DAYBUE STIX improves tolerability, and how the new DAYBUE patent changes the long-term franchise outlook. Management said the ADP optimization will not change inclusion/exclusion criteria; instead it will remove the 30 mg arm, emphasize 60 mg, increase central raters, refine site selection, and make statistical changes aimed at improving effect size. On DAYBUE STIX, they said persistency looks fairly similar to the liquid formulation, though families value the lower volume and the company continues to monitor tolerability. They also said the patent gives them confidence to invest through 2041 and that a fuller re-stressing of DAYBUE peak sales is likely to come in Q1 next year.
The quarter showed strong commercial momentum, with record DAYBUE sales, continued NUPLAZID growth, and a larger field force starting to broaden reach. Management also pointed to multiple runway-extending catalysts: the DAYBUE patent through 2041, EU expansion, and a pipeline that they believe could create value across ADP, LBDP, and MDD. The remlifanserin data were not cleanly positive on the primary endpoint, but management sounded more confident after seeing a 60 mg signal, dose response, and a favorable safety profile.
Remlifanserin still missed statistical significance on the primary ADP endpoint, so Phase III success is not yet established and management is relying on protocol optimization rather than a clear win. NUPLAZID guidance was narrowed because the field-force expansion is taking time to convert into prescriptions, implying that some expected benefits may land later. DAYBUE’s restart opportunity and STIX adoption look promising, but management acknowledged conversion should naturally moderate as the launch matures, and the company still needs to prove sustained penetration in community settings and internationally.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.7%
- Shares Outstanding
- 172.83M
- Float Shares
- 170.56M
of shares held by institutions
365 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ACAD, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Baker Bros. Advisors LP | 42.91M | ▲ 16.21K |
| Blackrock, Inc. | 22.95M | ▲ 432.31K |
| Vanguard Group Inc | 15.15M | ▼ 25.41K |
| Vanguard Portfolio Management LLC | 9.46M | ▲ 618.67K |
| State Street Corp | 7.65M | ▼ 1.43M |
| Rtw Investments, LP | 7.14M | 0 |
| Vanguard Capital Management LLC | 5.79M | ▲ 27.05K |
| Geode Capital Management, LLC | 3.37M | ▲ 14.17K |
| Dimensional Fund Advisors LP | 3.37M | ▼ 328.94K |
| Palo Alto Investors LP | 2.86M | ▼ 8.60K |
| Goldman Sachs Group Inc | 2.58M | ▲ 1.02M |
| Qube Research & Technologies Ltd | 2.46M | ▲ 17.89K |
Held by 461 ETFs
Biggest fund positions in ACAD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 15, 26 | Schneyer Mark C. | other | 6,815 |
| Oct 30, 26 | Schneyer Mark C. | sell | 3,321 |
| Aug 6, 26 | Schneyer Mark C. | other | 14,292 |
| Aug 6, 26 | Schneyer Mark C. | sell | 5,000 |
| Aug 5, 26 | Schneyer Mark C. | other | 5,849 |
| Aug 5, 26 | Schneyer Mark C. | other | 5,849 |
| Aug 5, 26 | Schneyer Mark C. | sell | 5,849 |
| Aug 6, 26 | Schneyer Mark C. | sell | 9,292 |
| Aug 6, 26 | Schneyer Mark C. | other | 14,292 |
| Jul 29, 26 | Thompson Elizabeth H.Z. | other | 32,272 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ACAD coverage
Recent articles, reports, and earnings notes.
No research on ACAD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ACAD report →ACADIA Pharmaceuticals Inc. $ACAD Stock: Bessemer Group Inc. Boosts Holdings
defenseworld.net · Nov 20
ACADIA Pharmaceuticals Eyes Deals as DAYBUE Growth Fuels Revenue Surge
defenseworld.net · Nov 19
ACADIA Pharmaceuticals Eyes Deals as DAYBUE Growth Fuels Revenue Surge
marketbeat.com · Nov 17
Acadia Pharmaceuticals Inc. (ACAD) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
businesswire.com · Nov 17
Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan
businesswire.com · Nov 16
ACADIA Pharmaceuticals Inc. $ACAD Shares Purchased by Allspring Global Investments Holdings LLC
defenseworld.net · Nov 13
Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal
businesswire.com · Nov 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.